Selegiline‐induced postural hypotension in Parkinson's disease: A longitudinal study on the effects of drug withdrawal

A. Churchyard,C. Mathias,A. Lees
DOI: https://doi.org/10.1002/1531-8257(199903)14:2<246::AID-MDS1008>3.0.CO;2-P
IF: 9.698
1999-03-01
Movement Disorders
Abstract:The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L‐dopa compared with those taking L‐dopa alone. Recently, we found that therapy with selegiline and L‐dopa was associated with selective systolic orthostatic hypotension which was abolished by withdrawal of selegiline. This unwanted effect on postural blood pressure was not the result of underlying autonomic failure. The aims of this study were to confirm our previous findings in a separate cohort of patients and to determine the time course of the cardiovascular consequences of stopping selegiline in the expectation that this might shed light on the mechanisms by which the drug causes orthostatic hypotension.
What problem does this paper attempt to address?